PR Newswire Clinical TrialsOriginal article
Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to Help Improve Critical Patient Outcomes
RegulatoryapprovedPositive
AI Analysis
Summary
Masimo announced FDA clearance of its smartSET pulse oximetry platform, which adds first-of-its-kind atrial fibrillation detection alongside previously cleared AI-enabled opioid-induced respiratory depression detection.
Outcome Details
FDA clearance for smartSET pulse oximetry platform featuring atrial fibrillation (AFib) detection, combined with previously cleared AI-enabled opioid-induced respiratory depression (OIRD) detection
Importance:5/10
Sentiment:
0.60
FDA clearancemedical devicepulse oximetryatrial fibrillationAIopioid-induced respiratory depressionpatient monitoring
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 17, 2026 1:00 PM